lactobacillus plantarum 931

*Lactobacillus plantarum* 931 (LB931) is a probiotic bacterial strain, recently reclassified as *Lactiplantibacillus plantarum* 931, that is being investigated as a live biotherapeutic product for the treatment of chronic rhinosinusitis (CRS). In clinical research led by the Royal Brisbane and Women's Hospital, the strain is administered as a component of a four-strain Lactobacillus nasal saline rinse (alongside *L. rhamnosus* GG, *L. paracasei* 8700:2, and *L. plantarum* HEAL9) to patients following nasal surgery. The therapeutic rationale is based on the strain's ability to colonize the sinonasal mucosa, restore a healthy microbial balance, and competitively exclude pathogenic bacteria such as *Staphylococcus aureus*. Additionally, LB931 is thought to modulate local inflammatory responses and enhance the mucosal barrier function, potentially reducing the recurrence of symptoms in chronic rhinosinusitis patients.

Other names

L. plantarum 931Lactiplantibacillus plantarum 931